The Company was originally promoted by Mr. A. M. Rao and incorporated as Emgi Pharmaceuticals & Chemicals Private Limited on September 22, 1988 with Registrar of Companies of Karnataka, Bangalore. On Mr. Rao's accidental death the Company was put for a sale. In 1989 Mr. Santosh Varalwar and Mr. Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Limited and commenced manufacturing of Bulk Drugs in 1991. Both the present promoters are professionals with more than a decade of experience in Chemicals and Pharmaceutical Industry. The Company was converted into a Public Limited Company on April 4, 1994. The name of the Company has been changed to Vivimed Labs Limited on April 22, 1997. The name of the Company has been changed to incorporate present Promoter's initials in the Company's name. The Company's manufacturing Unit is located at Bidar, Karnataka, where it was originally engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Bulk Drugs like Ibuprofen etc. However, due to downward price movement in the products of the Company during 1995, it gradually moved over to manufacturing Specialty Chemicals and cosmetic ingredients like Triclosan, Avis etc. catering to global and domestic markets. Vivimed started production of Triclosan with a very small capacity of 5 MT p.a, in the year 1999 and increased its capacity to 225 MT p.a. over a period of next 5 years. The production capacity has been doubled by adding one more production block in March 2004. The Company currently employs over 250 personnel including contract laborers. Vivimed's Turnover has grown from Rs. 751.85 lacs in FY1999 to Rs. 4,042.55 lacs in FY2004 and its Net profit grew from Rs. 15.26 lacs in FY1999 to Rs. 400.28 lacs in FY2004. The Turnover of the Company for 6 months period ended September 30, 2004 is Rs. 2322.60 Lacs and Net Profit is Rs.249.24 lacs. As at September 30, 2004, the Networth of the Company was Rs. 1850.15 lacs. The Company has ISO 9001:2000 certification for its Quality Management System related to manufacturing process and marketing aspects. Further, the Company is in the process of obtaining ISO 14001 certification for Environmental Management System for which two Audits have already been completed. Major events In -the history of the Company is given below: Year Event 1988 & * Incorporated on September 22, 1988 1989 * Death of original promoter Mr. A. M. Rao * Acquired by Mr. Santosh Varalwar and Mr. Subhash Varalwar 1990 * Commenced production of Non-Steroidal Anti-Inflammatory Drug (NSAID) - IBUPROFEN. 1994 * Diversification and Expansion of Product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal). 1995 * Diversification into specialty chemicals by production of Triclosan. 1996 * R&D was commenced with facilities having an integrated instrumentation for organic synthesis, Microbiology and pre-formulation studies. 1997 * Process Innovation of Anti-bacterial and clearance of innovative route of synthesis for Triclosan. * Grant of patent for VIV-20 (Triclosan) by the Indian Patents Office. 1998- * Qualified for supply to Unilever's Asian locations after 99 Audit of manufacturing facility by a team of Unilever Plc. * Triclosan customer base expanded to UK, France, Germany as well as domestic market; 2002 * Approved by Unilever group Companies in Asian/Middle & Far East Companies for usage of Enamel Protective Agent manufactured by the Company in their oral care formulations. * Developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends. * Vivimed emerges as a second chemical Company located outside USA/Europe to get the US EPA's registration for Triclosan as 99% ingredient. * Vivimed's Quality Management System gets ISO 9001:2000 certification. 2003 * Signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123. * Commencement of EMS Audit for ISO 14001 certification. 2004 * Introduced new products for anti-dandruff and skin care application * Triclosan production capacity increased from 225 MT p.a. to 480 MT p.a. * Developed novel synthetic process to manufacture a premium Anti-oxidant and Anti-cancer molecule branded as VINTOX 2005 * The Company has received the State Award for Excellence in Exports (SSI GOLD) from Karnataka State Government for excellence in exports * The Company has received 1 star export house status in 2005. 2009 - Vivimed Labs Ltd has informed BSE that Mr. Y Krishna has been appointed as an Additional Director on the Board of the Company with effect from June 30, 2009 in the Board Meeting of the Company held on June 30, 2009. 2010 - Vivimed Labs Ltd has appointed Mr. Nixon Patel as an Additional Director of the Company with effect from June 28, 2010. Mr. Nixon Patel has been appointed as an Independent Director on the Board. 2011 -Vivimed Labs Incorporation of Foreign Subsidiaries namely, Vivimed Labs Mauritius Ltd., Mauritius, Vivimed Labs UK Ltd., UK and Vivimed Labs Spain, SL, Spain. -Vivimed Labs has accquired majority Stake in Octtantis Nobel Labs Private Ltd. -Vivimed Labs Acquired equity stake in Klar Sehen Pvt. Ltd. -Vivimed Labs Acquired Uquifa Spain and Uquifa Mexico 2012 -Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona. -Mr. K. Yugandhar has been appointed as Company Secretary of the company 2013 -Vivimed acquires a US FDA approved formulation manufacturing facility. -Vivimed are Exhibiting at HPCi - Mumbai. 2014 -Vivimed receives the PIC/S GMP approval for one of its pharmaceuticals manufacturing facilities in Hyderabad. -Vivimed Labs - Grant of Options under Vivimed Labs ESOS 2010. 2016 -Vivimed's FDF facility in Alathur completed successful USFDA inspection -Vivimed launch Jarocolr Sapphire Blue 2020 -Vivimed Launches its own brand of favipiravir.